Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy

Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions.

Citation:
Chin WL, Cook AM, Chee J, ……. McDonnell AM, Hon CC, Moody J, Anderson D, Yip S, Cummins MM, …….. Lassmann T, Lesterhuis WJ. Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy. Cell Rep Med. 2025;6(1).

Keywords:
CD8(+) T effector memory cells; ICT; PD-L1; biomarkers; cancer; immune checkpoint therapy; mesothelioma; peripheral blood; platinum chemotherapy; response; single-cell RNA sequencing.

Abstract:
Platinum-based chemotherapy in combination with anti-PD-L1 antibodies has shown promising results in mesothelioma. However, the immunological mechanisms underlying its efficacy are not well understood and there are no predictive biomarkers to guide treatment decisions.